On September 10, 2025, MEI Pharma, Inc. changed its name to Lite Strategy, Inc. and its ticker symbol to LITS. We are a pharmaceutical company that has been developing novel and differentiated cancer therapies.
Revenue declined 100.0% YoY. The question is whether this is cyclical or a structural shift.
ROIC dropped from 32.65% to -55.21%, capital efficiency is deteriorating. Negative free cash flow of -$21M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (FY)
$0.00
▼ -100.0% YoY
Net Income (TTM)
-$61M
▼ -189.7% YoY
Op. Margin
—
ROIC
-68.53%
▼ -87.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$10M
▲ +58.7% YoY
Op. Cash Flow (TTM)
-$10M
▲ +58.7% YoY
Net Debt
-$8M
Net Cash Position
Cash & Equiv.
$8M
Continue Research